TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas

Virchows Archiv

Volumn 462, Issue 3, 2013, Pages 281-287

  Xu, Hong Tao ^a   Liu, Yang ^a   Liu, Shu Li ^a   Miao, Yuan ^a   Li, Qing Chang ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

C8orf4; Colorectal cancer; Ovarian cancer; Receiver operator characteristic curve; Thyroid cancer 1

Indexed keywords

PROTEIN; THYROID CANCER 1 PROTEIN; UNCLASSIFIED DRUG; C8ORF4 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER LOCALIZATION; COLORECTAL CARCINOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; AGED; AREA UNDER THE CURVE; BIOSYNTHESIS; CELL DIFFERENTIATION; COLORECTAL TUMOR; DIFFERENTIAL DIAGNOSIS; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER CURVE; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876081493     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1375-7     Document Type: Article

References (32)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. Marsden DE, Friedlander M, Hacker NF (2000) Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 19(1):11-19
3. Merritt MA, Cramer DW (2010) Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark 9(1-6):287-305
4. Romero I, Bast RC Jr (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153(4):1593-1602
5. Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID (2012) Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol 27(6):707-719
6. Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP, Death AK (2004) TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res 64(8):2766-2773
7. Friedman JB, Brunschwig EB, Platzer P, Wilson K, Markowitz SD (2004) C8orf4 is a transforming growth factor B induced transcript downregulated in metastatic colon cancer. Int J Cancer 111(1):72-75
8. Chua EL, Young L, Wu WM, Turtle JR, Dong Q (2000) Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics 69(3):342-347
9. Kim Y, Kim J, Park J, Bang S, Jung Y, Choe J, Song K, Lee I (2006) TC1(C8orf4) is upregulated by IL-1beta/TNF-alpha and enhances proliferation of human follicular dendritic cells. FEBS Lett 580(14):3519-3524
10. Yang ZQ, Moffa AB, Haddad R, Streicher KL, Ethier SP (2007) Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways. Int J Cancer 121(6):1265-1273
11. Park J, Jung Y, Kim J, Kim KY, Ahn SG, Song K, Lee I (2007) TC1 (C8orf4) is upregulated by cellular stress and mediates heat shock response. Biochem Biophys Res Commun 360(2):447-452
12. Kim J, Kim Y, Kim HT, Kim DW, Ha Y, Kim CH, Lee I, Song K (2009) TC1(C8orf4) is a novel endothelial inflammatory regulator enhancing NF-kappaB activity. J Immunol 183(6):3996-4002
13. Wang YD, Bian GH, Lv XY, Zheng R, Sun H, Zhang Z, Chen Y, Li QW, Xiao Y, Yang QT, Ai JZ, Wei YQ, Zhou Q (2008) TC1 (C8orf4) is involved in ERK1/2 pathway-regulated G(1)- to S-phase transition. BMB Rep 41(10):733-738
14. Jung Y, Bang S, Choi K, Kim E, Kim Y, Kim J, Park J, Koo H, Moon RT, Song K, Lee I (2006) TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby. Cancer Res 66(2):723-728
15. Kim B, Koo H, Yang S, Bang S, Jung Y, Kim Y, Kim J, Park J, Moon RT, Song K, Lee I (2006) TC1(C8orf4) correlates with Wnt/beta-catenin target genes and aggressive biological behavior in gastric cancer. Clin Cancer Res 12(11 Pt 1):3541-3548
16. Gall C, Xu H, Brickenden A, Ai X, Choy WY (2007) The intrinsically disordered TC-1 interacts with Chibby via regions with high helical propensity. Protein Sci 16(11):2510-2518
17. Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT (2003) Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway. Nature 422(6934):905-909
18. Xu HT, Li QC, Dai SD, Xie XM, Liu DI, Wang EH (2011) The expression patterns and correlations of chibby, beta-catenin, and DNA methyltransferase-1 and their clinicopathological significance in lung cancers. APMIS 119(11):750-758
19. Li FQ, Mofunanya A, Fischer V, Hall J, Takemaru K (2010) Nuclear-cytoplasmic shuttling of Chibby controls beta-catenin signaling. Mol Biol Cell 21(2):311-322
20. de Melo Martins PC, Parise Junior O, Pereira Hors C, Villela Miguel RE, da Costa Andrade VC, Garicochea B (2007) C8orf4/TC-1 (thyroid cancer-1) gene expression in thyroid cancer and goiter. ORL J Otorhinolaryngol Relat Spec 69(2):127-130
21. Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP (2006) Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 66(24):11632-11643
22. Zhang J, Gao Y, Zhao X, Guan M, Zhang W, Wan J, Yu B (2011) Investigation of copy-number variations of C8orf4 in hematological malignancies. Med Oncol 28(Suppl 1):S647-S652
23. Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrozek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ (2009) Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 106(31):12950-12955
24. Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, Lee KY (2010) CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol 40(3):208-213
25. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF 3rd, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN (2003) Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63(17):5243-5250
26. Kimelman D, Xu W (2006) beta-Catenin destruction complex: insights and questions from a structural perspective. Oncogene 25(57):7482-7491
27. Huang H, He X (2008) Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20(2):119-125
28. Xu HT, Yang LH, Li QC, Liu SL, Liu D, Xie XM, Wang EH (2011) Disabled-2 and Axin are concurrently colocalized and underexpressed in lung cancers. Hum Pathol 42(10):1491-1498
29. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF (2008) Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 18(5):954-962
30. Schmid S, Bieber M, Zhang F, Zhang M, He B, Jablons D, Teng NN (2011) Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer 21(6):975-980
31. Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, Ronnett BM (2006) Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 30(9):1130-1139
32. McCluggage WG, Young RH (2005) Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 22(1):3-32